FHIT Antibody | 7455

FHIT Antibody | 7455 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: Predicted species reactivity based on immunogen sequence: Bovine: (88%) , Rat: (72%)

Immunogen: FHIT antibody was raised against an 18 amino acid peptide near the carboxy terminus of human FHIT.
The immunogen is located within the last 50 amino acids of FHIT .

Research Area: Apoptosis

Tested Application: E, WB, IF

Application: FHIT antibody can be used for detection of FHIT by Western blot at 1 - 2 μg/ml.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: FHIT antibody is human and mouse reactive.

Positive Control 1: Cat. No. 1201 - HeLa Cell Lysate

Positive Control 2: Cat. No. 17-001 - HeLa Cell Slide

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 16 kDa
Observed: 15kDa

Validation: N/A

Isoform: N/A

Purification: FHIT Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: FHIT Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: FHIT antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.

Alternate Name: FHIT Antibody : FRA3B, AP3AaseAP3A hydrolase, AP3Aase

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: FHIT is member of the histidine triad gene family and is a diadenosine involved in purine metabolism (1) . FHIT is also thought to be a tumor suppressor gene and is involved in multiple apoptotic pathways (1, 2) . The FHIT gene encompasses the common fragile site FRA3B on chromosome 3, where carcinogen-induced damage can lead to translocations and aberrant transcripts of this gene (3) . Aberrant transcripts from this gene have been found in multiple carcinomas (4) .